Clinical Significance And Expression Of IGF-1and IGFBP-3in Serum Of Patients With Non-small Cell Lung Cancer During Chemotherapy

Objective： There are many different kinds of treatments for lung cancer, butchemotherapy is the most important method for lung cancer treatment. However it ismore important for evaluation of the efficacy of chemotherapy regimens to change intime than chemotherapy for improving the symptoms of patients. Insulin-like growthfactor1(IGF-1) can strongIy slimulate the proliferation of a variety of cancer cells，incIuding lung cancer cells, and insulin like growth factor binding protein3(IGFBP-3)may have a role in inhibiting the growth of lung cancer cells. Therefore this study wasto discuss clinical significance and expression of IGF-1and IGFBP-3in serum ofpatients with non-small cell lung cancer (NSCLC) pre-and post-chemotherapy, andthen explore the IGF-1and IGFBP-3is expected to become a very good indicator of theefficacy of chemotherapy in NSCLC clinical prediction.Methods：Patients diagnosed with NSCLC, and were confirmed by histopathologyevaluable lesions, in line chemotherapy indication. Prior to the first cycle ofchemotherapy on day1and day31before each cycle of chemotherapy venous blood3mL, centrifugation, the upper serum stored at-frozen80℃. By ELISA in serum weremeasured before and after chemotherapy, IGF-1, IGFBP-3levels.Results: The serum IGF-1and IGFBP-3levels of normal control group is [X±S,199.54±78.66μg/L,4060.2±765.33μg/L], respectively.The serum IGF-1level s of normal control group is lower than the cases with NSCLC in pre-chemotherapy（P＜0.01）.The serum IGFBP-3levels of normal control group is higher than the cases with NSCLC in pre-chemotherapy（P＜0.01）.There is no differce between the serum IGF-1and IGFBP-3levels of normal control group and the cases with NSCLC in post-chemotherapy (P>0.05).For the cases with NSCLC in pre-chemotherapy, serum levels of IGF-1[X±S,355.21±101.22μg/L] were significantly decreased than those[X±S227.02±117.08μg/L] after treatment in60cases（P＜0.01）. And serum levels of IGFBP-3[X±S,3005.41±1034.14μg/L] before treatment were significantly higher than those[X±S,3508.78±1040.65μg/L] after treatment in60cases of NSCLC（P＜0.01）. There are43cases effective and ineffective in17cases in60patients with NSCLC by chemotherapy. For the cases with NSCLC ineffective group,serum levels of IGF-1[X±S，362.04±96.05μg/L] in pre—chemotherapy were significantly decreased than those[X±S,140.13±52.37μg/L] in post—chemotherapy（P＜0.01）. And Serum levels of IGFBP-3[X±S,3148.46±100.7μg/L] before treatment were significantly higher than those[X±S,3365.35±998.78μg/L] after treatment in effective group（P＜0.01）. And for the cases with NSCLC in ineffective group, there was no statistically significant difference about serum IGF-I and IGFBP-3level in pre—chemotherapy and in post—chemotherapy(P＞0.05).Conclusion：IGF-1and IGFBP-3concentrations were negatively correlated in NSCLC patients before chemotherapy, and serum IGF-1levels were significantly decresed in post—chemotherapy than those in pre—chemotherapy in effective group(IGF-1and IGFBP-3concentrations were negatively correlated in effective group). These resuIts suggested that IGF-l and lGFBP-3pIay important roles in the growthof NSCLC．Serum examination of IGF-l and lGFBP-3may have potential clinical value to assess the efficacy of chemotherapy．...